SFRP2+ fibroblasts epigenetically drive DCIS-to-IDC progression by downregulating expression to activate pro-invasive signaling pathways and remodel the immunosuppressive microenvironment, enabling malignant transition (40). Here, SFRP2 is linked to ductal breast carcinoma in situ.